Overcoming Challenges With the Adoption of Point-of-Care Testing - POCTRN

Center news

null Overcoming Challenges With the Adoption of Point-of-Care Testing

Overcoming Challenges With the Adoption of Point-of-Care Testing

From Technology Push and Clinical Needs to Value Propositions


Major technical challenges often prevent developers from producing new point-of-care technologies that deliver the required clinical performance in the intended settings of use. However, even when devices meet clinical requirements, they can fail to be adopted and successfully implemented. Adoption barriers occur when decision makers do not understand the “value proposition” of new technologies. Current discussions of value in the context of point-of-care testing focus predominantly on the intended use and performance of the device from the manufacturer's point of view. However, the perspective of potential adopters in determining whether new devices provide value is also important, as is the opinion of all stakeholders who will be impacted. Incorporating value concepts into decisions made across the full development-to-adoption continuum can increase the likelihood that point-of-care testing will have the desired impact on health care delivery and patient outcomes. This article discusses how various approaches to technology development impact adoption and compares the characteristics of these approaches to emerging value concepts. It also provides an overview of value initiatives and tools that are being developed to support the evaluation of value propositions. These are presented for a range of technology adoption decision contexts, with particular applicability to point-of-care testing. Expanding the focus of research to address gaps in both the creation and evaluation of value propositions is imperative in order for value concepts to positively influence the adoption of point-of-care testing.

Read the full article >

RADx: Rapid Acceleration of Diagnostics

In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADx®) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.


In the News 

Two New Over-the-Counter At-Home COVID-19 Tests Brought to U.S. Market Quickly by Biden-Harris Administration

New HHS actions add to Biden administration efforts to increase access to easy-to-use over-the-counter COVID-19 tests

NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests

The need for new test verification and regulatory support for innovative diagnostics

NIH-funded screening study builds case for frequent COVID-19 antigen testing

RADx partnerships speed new COVID testing

One Year of RADx Tech Success

Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort 

Innovative COVID-19 Testing RADx Tech Reports Unveiled in Special Issue of IEEE Open Journal of Engineering in Medicine and Biology

Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured Smartphone-Based COVID-19 Rapid Test

RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing (Login Required)

VIC Foundry, Inc. Receives NIH RADx Funding for Development of an At-home Molecular Diagnostic Test for COVID-19

Ceres Nanosciences Opens Advanced Particle Manufacturing Plant in Northern Virginia to Expand Nanotrap® Particle Manufacturing Capacity for COVID-19 Testing

COVID-19 Testing: Three Breakthrough Solutions in the RADx Initiative

NIH Director: Collaboration Amid Chaos, and Biden’s First 100 Days - How Francis Collins sees the COVID response changing with the new administration

The National Strategy From the COVID-19 Response and Pandemic Preparedness

Winners of HHS Design-a-thon to Develop Innovative Digital Health Tools for COVID-19 At-Anywhere Diagnostic Tests Announced

The Need for More and Better Testing for COVID-19